Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Article Details How to Cite Ko, J. ., McMichael, A. ., Tosti, A. ., Ito, T. ., Dutronc, Y. ., Yu, G. ., Chen, Y. ., Murage, M. ., Chiasserini, C. ., & Mostaghimi, A. . (2023). Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata. SKIN The Journal of Cutaneous Medicine, 7(6), s295.
Key Points Question What is the benefit of uptitration to baricitinib, 4 mg, for 24 weeks among patients with severe alopecia areata who did not respond to baricitinib, 2 mg (Severity of Alopecia Tool score >20), after 52 weeks of therapy? Findings In this pooled analysis of 2 phase 3 randomized clinical trials, 25% of baricitinib, 2 mg, nonresponders who uptitrated to baricitinib, 4 mg, achieved at least 80% scalp coverage (Severity of Alopecia Tool score ≤20) by week 76.
This work is licensed under a Creative Commons Attribution 4.0 International License. All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose.
Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials Autores: Justin M. Ko, Tiffany T. Mayo, Wilma F. Bergfeld, Yves Dutronc, Guanglei Yu, Susan G. Ball, Najwa Somani, Brittany G. Craiglow Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 159, Nº. 9, 2023, págs.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
